MedDataX Logo

Impact of a Predictive Model on Sentinel Lymph Node Biopsy in Initially Lymph Node-positive, HER2-positive Breast Cancer

NCT06149377 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 716

Last updated 2023-12-13

No results posted yet for this study

Summary

The aim of the study was to develop and validate a nomogram to assess axillary pathological complete response (pCR) in patients with initially lymph node-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer and test its performance in guiding patient selection for sentinel lymph node biopsy (SLNB) following neoadjuvant systemic therapy (NST).

Conditions

  • Breast Cancer
  • Sentinel Lymph Node

Interventions

PROCEDURE

Test cohort

Sponsors & Collaborators

  • Fujian Medical University Union Hospital

    lead OTHER

Principal Investigators

  • China Fujian · Fujian Medical University Union Hospital

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-01
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • China

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06149377 on ClinicalTrials.gov